Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

Edward R Kastenhuber; John Craig; Jon Ramsey; Kevin M Sullivan; Julien Sage; Sofia de Oliveira; Kimberly J Riehle; John D Scott; John D Gordan; Nabeel Bardeesy; Ghassan K Abou-Alfa

doi:10.2147/JHC.S194764

Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

J Hepatocell Carcinoma. 2019 Jan 31:6:41-48. doi: 10.2147/JHC.S194764. eCollection 2019.

Authors

Edward R Kastenhuber^{1

2}, John Craig³, Jon Ramsey⁴, Kevin M Sullivan⁵, Julien Sage^{6

7}, Sofia de Oliveira⁸, Kimberly J Riehle⁵, John D Scott⁵, John D Gordan⁹, Nabeel Bardeesy^{10

11}, Ghassan K Abou-Alfa^{1

12}

Affiliations

¹ Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, abou-alg@mskcc.org.
² Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Fibrolamellar Cancer Foundation, Greenwich, CT, USA.
⁴ Department of Biochemistry, University of Vermont Cancer Center, Burlington, VT, USA.
⁵ Northwest Liver Research Program, University of Washington, Seattle, WA, USA.
⁶ Department of Pediatrics, Stanford University, Stanford, CA, USA.
⁷ Department of Genetics, Stanford University, Stanford, CA, USA.
⁸ Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI, USA.
⁹ Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
¹⁰ Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
¹¹ Department of Medicine, Harvard Medical School, Boston, MA, USA.
¹² Department of Medicine, Weill Cornell School of Medicine, New York, NY, USA, abou-alg@mskcc.org.

Abstract

Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.

Keywords: adolescent; cyclic AMP-dependent protein kinase catalytic subunit; fibrolamellar carcinoma; fusion oncogene; heat shock protein 40; liver cancer; young adult.

Abstract

Grants and funding